uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.30−0.48 (-2.31%)
Close on Nov 18, 2026Market cap $1.41BP/E –Yield –
uniQure total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
uniQure's total debt was $50.15M at Jun 30, 2026. For fiscal 2025 it was $49.70M, down 3.2% from the year before. Over ten years it grew 9.4% a year on average. The highest annual figure on record is $102.79M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.70M | -3.2% |
| FY2024 | Dec 31, 2024 | $51.32M | -49.6% |
| FY2023 | Dec 31, 2023 | $101.75M | -1.0% |
| FY2022 | Dec 31, 2022 | $102.79M | +1.8% |
| FY2021 | Dec 31, 2021 | $100.96M | +183.5% |
| FY2020 | Dec 31, 2020 | $35.62M | -1.2% |
| FY2019 | Dec 31, 2019 | $36.06M | +1.7% |
| FY2018 | Dec 31, 2018 | $35.47M | +70.6% |
| FY2017 | Dec 31, 2017 | $20.79M | +2.7% |
| FY2016 | Dec 31, 2016 | $20.24M | +0.1% |
| FY2015 | Dec 31, 2015 | $20.21M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $50.15M | -3.3% |
| Q1 FY2026 | Mar 31, 2026 | $49.94M | -3.2% |
| Q4 FY2025 | Dec 31, 2025 | $49.70M | -3.2% |
| Q3 FY2025 | Sep 30, 2025 | $51.88M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | $51.84M | -49.4% |
| Q1 FY2025 | Mar 31, 2025 | $51.59M | -49.5% |
| Q4 FY2024 | Dec 31, 2024 | $51.32M | -49.6% |
| Q3 FY2024 | Sep 30, 2024 | $51.11M | -49.6% |
| Q2 FY2024 | Jun 30, 2024 | $102.51M | +1.4% |
| Q1 FY2024 | Mar 31, 2024 | $102.12M | -1.1% |
| Q4 FY2023 | Dec 31, 2023 | $101.75M | -1.0% |
| Q3 FY2023 | Sep 30, 2023 | $101.43M | -0.9% |
| Q2 FY2023 | Jun 30, 2023 | $101.11M | -0.8% |
| Q1 FY2023 | Mar 31, 2023 | $103.25M | +1.8% |
| Q4 FY2022 | Dec 31, 2022 | $102.79M | +1.8% |
| Q3 FY2022 | Sep 30, 2022 | $102.39M | +43.2% |
| Q2 FY2022 | Jun 30, 2022 | $101.89M | +44.0% |
| Q1 FY2022 | Mar 31, 2022 | $101.42M | +43.9% |
| Q4 FY2021 | Dec 31, 2021 | $100.96M | +183.5% |
| Q3 FY2021 | Sep 30, 2021 | $71.49M | +101.4% |
| Q2 FY2021 | Jun 30, 2021 | $70.78M | +100.1% |
| Q1 FY2021 | Mar 31, 2021 | $70.47M | +94.6% |
| Q4 FY2020 | Dec 31, 2020 | $35.62M | -1.2% |
| Q3 FY2020 | Sep 30, 2020 | $35.49M | -1.2% |
| Q2 FY2020 | Jun 30, 2020 | $35.37M | -1.1% |
| Q1 FY2020 | Mar 31, 2020 | $36.21M | +1.6% |
| Q4 FY2019 | Dec 31, 2019 | $36.06M | +1.7% |
| Q3 FY2019 | Sep 30, 2019 | $35.93M | +73.5% |
| Q2 FY2019 | Jun 30, 2019 | $35.78M | +71.5% |
| Q1 FY2019 | Mar 31, 2019 | $35.63M | +71.2% |
| Q4 FY2018 | Dec 31, 2018 | $35.47M | +70.6% |
| Q3 FY2018 | Sep 30, 2018 | $20.71M | +0.6% |
| Q2 FY2018 | Jun 30, 2018 | $20.87M | +1.9% |
| Q1 FY2018 | Mar 31, 2018 | $20.81M | +2.2% |
| Q4 FY2017 | Dec 31, 2017 | $20.79M | +2.7% |
| Q3 FY2017 | Sep 30, 2017 | $20.59M | – |
| Q2 FY2017 | Jun 30, 2017 | $20.47M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $20.24M | – |
See a number that looks wrong?